ZA200902384B - Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors - Google Patents
Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitorsInfo
- Publication number
- ZA200902384B ZA200902384B ZA200902384A ZA200902384A ZA200902384B ZA 200902384 B ZA200902384 B ZA 200902384B ZA 200902384 A ZA200902384 A ZA 200902384A ZA 200902384 A ZA200902384 A ZA 200902384A ZA 200902384 B ZA200902384 B ZA 200902384B
- Authority
- ZA
- South Africa
- Prior art keywords
- compositions
- protein kinase
- kinase inhibitors
- heteroaryl compounds
- conditions
- Prior art date
Links
- 125000001072 heteroaryl group Chemical group 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
- -1 Heteroaryl Compound Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85313506P | 2006-10-19 | 2006-10-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200902384B true ZA200902384B (en) | 2010-07-28 |
Family
ID=39144905
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200902384A ZA200902384B (en) | 2006-10-19 | 2007-10-18 | Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors |
Country Status (17)
Country | Link |
---|---|
US (2) | US7968556B2 (xx) |
EP (1) | EP2078018B1 (xx) |
JP (1) | JP5513119B2 (xx) |
KR (1) | KR101451290B1 (xx) |
CN (1) | CN101679432B (xx) |
AT (1) | ATE549336T1 (xx) |
AU (1) | AU2007309468B2 (xx) |
BR (1) | BRPI0717773A2 (xx) |
CA (1) | CA2666624C (xx) |
ES (1) | ES2383370T3 (xx) |
HK (1) | HK1131146A1 (xx) |
IL (1) | IL198116A (xx) |
MX (1) | MX2009004019A (xx) |
NZ (1) | NZ576279A (xx) |
RU (1) | RU2474582C2 (xx) |
WO (1) | WO2008051494A1 (xx) |
ZA (1) | ZA200902384B (xx) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7989459B2 (en) | 2006-02-17 | 2011-08-02 | Pharmacopeia, Llc | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors |
US20090281075A1 (en) * | 2006-02-17 | 2009-11-12 | Pharmacopeia, Inc. | Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors |
AR063142A1 (es) | 2006-10-04 | 2008-12-30 | Pharmacopeia Inc | Derivados de 2-(bencimidazolil) purina y purinonas 6-sustituidas utiles como inmunosupresores,y composiciones farmaceuticas que los contienen. |
WO2008043019A1 (en) | 2006-10-04 | 2008-04-10 | Pharmacopeia, Inc | 8-substituted 2-(benzimidazolyl) purine derivatives for immunosuppression |
US7902187B2 (en) | 2006-10-04 | 2011-03-08 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
WO2009062059A2 (en) * | 2007-11-08 | 2009-05-14 | Pharmacopeia, Inc. | Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors |
GB0725218D0 (en) * | 2007-12-24 | 2008-02-06 | Syngenta Ltd | Chemical compounds |
EP2268623B9 (en) | 2008-03-17 | 2018-02-28 | Ambit Biosciences Corporation | Quinazoline derivatives as raf kinase modulators and methods of use thereof |
WO2010016490A1 (ja) * | 2008-08-05 | 2010-02-11 | 第一三共株式会社 | イミダゾピリジン-2-オン誘導体 |
WO2011031308A1 (en) * | 2009-09-09 | 2011-03-17 | Cytokinetics, Incorporated | Novel combinations |
GB0917934D0 (en) * | 2009-10-13 | 2009-11-25 | Syngenta Ltd | Herbicidal compounds |
EP2493472B1 (en) | 2009-10-26 | 2016-12-07 | Signal Pharmaceuticals, LLC | Methods of synthesis and purification of heteroaryl compounds |
CN102762568A (zh) | 2009-12-23 | 2012-10-31 | 伊兰药品公司 | 作为polo样激酶的抑制剂的蝶啶酮 |
EP2992878A1 (en) * | 2010-02-03 | 2016-03-09 | Signal Pharmaceuticals, LLC | Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors |
US9138309B2 (en) | 2010-02-05 | 2015-09-22 | Allergan, Inc. | Porous materials, methods of making and uses |
US9205577B2 (en) * | 2010-02-05 | 2015-12-08 | Allergan, Inc. | Porogen compositions, methods of making and uses |
US11202853B2 (en) * | 2010-05-11 | 2021-12-21 | Allergan, Inc. | Porogen compositions, methods of making and uses |
CA2798578C (en) | 2010-05-21 | 2015-12-29 | Chemilia Ab | Novel pyrimidine derivatives |
EP2390245A1 (en) * | 2010-05-26 | 2011-11-30 | Nabriva Therapeutics AG | Enantiomerically pure amines |
SG186341A1 (en) * | 2010-06-24 | 2013-01-30 | Takeda Pharmaceutical | Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors |
US20130196990A1 (en) | 2010-10-06 | 2013-08-01 | Junya Qu | Benzimidazole Derivatives As PI3 Kinase Inhibitors |
CN102093421B (zh) * | 2011-01-28 | 2014-07-02 | 北京康辰药业有限公司 | 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
RU2013147417A (ru) | 2011-03-24 | 2015-04-27 | Кемилиа Аб | Новые производные пиримидина |
CN107157990B (zh) | 2011-10-19 | 2020-01-07 | 西格诺药品有限公司 | 利用tor激酶抑制剂治疗癌症 |
UA114496C2 (uk) | 2011-12-02 | 2017-06-26 | Сігнал Фармасьютікалз, Елелсі | ФАРМАЦЕВТИЧНІ КОМПОЗИЦІЇ 7-(6-(2-ГІДРОКСИПРОПАН-2-ІЛ)ПІРИДИН-3-ІЛ)-1-((ТРАНС)-4-МЕТОКСИЦИКЛОГЕКСИЛ)-3,4-ДИГІДРОПІРАЗИНО[2,3-b]ПІРАЗИН-2(1H)-ОНУ, ЇХ ТВЕРДІ ФОРМИ І СПОСОБИ ЇХ ЗАСТОСУВАННЯ |
EA028462B1 (ru) | 2012-02-24 | 2017-11-30 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Способы лечения немелкоклеточного рака легких на поздних стадиях c применением комбинированного лечения с ингибитором киназы tor |
KR20210071101A (ko) * | 2012-03-15 | 2021-06-15 | 시그날 파마소티칼 엘엘씨 | Tor 키나제 억제자를 사용하는 암의 치료 |
EA028434B1 (ru) | 2012-03-15 | 2017-11-30 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Лечение рака ингибиторами tor киназы |
KR102057357B1 (ko) * | 2012-03-15 | 2019-12-18 | 시그날 파마소티칼 엘엘씨 | Tor 키나제 억제제를 사용한 암의 치료 |
EP2825169B1 (en) | 2012-03-15 | 2018-05-09 | Signal Pharmaceuticals, LLC | Treatment of cancer with tor kinase inhibitors |
AU2013202768B2 (en) | 2012-10-18 | 2015-11-05 | Signal Pharmaceuticals, Llc | Treatment of cancer with TOR kinase inhibitors |
EA039396B1 (ru) * | 2012-10-18 | 2022-01-24 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Лечение рака молочной железы с тройным негативным фенотипом ингибиторами tor-киназы |
AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
SG10201600149VA (en) | 2012-11-21 | 2016-02-26 | Ptc Therapeutics Inc | Substituted reverse pyrimidine bmi-1 inhibitors |
BR112015016997A2 (pt) | 2013-01-16 | 2017-07-11 | Signal Pharm Llc | composto, composição farmacêutica e método para o tratamento ou prevenção de câncer de mama |
US9358232B2 (en) | 2013-04-17 | 2016-06-07 | Signal Pharmaceuticals, Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy |
CA2908353C (en) | 2013-04-17 | 2021-11-02 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
WO2014172426A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
BR112015026297B1 (pt) | 2013-04-17 | 2022-08-23 | Signal Pharmaceuticals, Llc | Uso de um inibidor da quinase tor e quinazolinona 5-substituída, composição farmacêutica que os compreende, e kit |
TW201527300A (zh) | 2013-04-17 | 2015-07-16 | Signal Pharm Llc | 關於1-乙基-7-(2-甲基-6-(1H-1,2,4-***-3-基)吡啶-3-基)-3,4-二氫吡并[2,3-b]吡-2(1H)-酮之醫藥調配物、方法、固態型式及使用方法 |
JP6382948B2 (ja) | 2013-04-17 | 2018-08-29 | シグナル ファーマシューティカルズ,エルエルシー | 癌を治療するためのtorキナーゼ阻害剤及びシチジン類似体を含む組合せ療法 |
US9937169B2 (en) | 2013-04-17 | 2018-04-10 | Signal Pharmaceuticals, Llc | Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy |
CN113831345A (zh) | 2013-05-29 | 2021-12-24 | 西格诺药品有限公司 | 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途 |
EP3039015B1 (en) | 2013-08-30 | 2019-10-30 | PTC Therapeutics, Inc. | Substituted pyrimidine bmi-1 inhibitors |
WO2015076800A1 (en) | 2013-11-21 | 2015-05-28 | Ptc Therapeutics, Inc. | Substituted pyridine and pyrazine bmi-1 inhibitors |
GB201321739D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
EP3131551A4 (en) | 2014-04-16 | 2017-09-20 | Signal Pharmaceuticals, LLC | SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
JP2017514806A (ja) | 2014-04-16 | 2017-06-08 | シグナル ファーマシューティカルズ,エルエルシー | Torキナーゼ阻害剤組み合わせ療法を使用して癌を治療する方法 |
NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
WO2015160882A1 (en) | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
NZ629796A (en) | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
AU2015289929A1 (en) | 2014-07-14 | 2017-03-02 | Signal Pharmaceuticals, Llc | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
US20170335324A1 (en) | 2014-11-12 | 2017-11-23 | The General Hospital Corporation | Methods for treating neurodegenerative diseases |
AU2016301315C1 (en) * | 2015-08-03 | 2022-07-07 | Sumitomo Pharma Oncology, Inc. | Combination therapies for treatment of cancer |
SG11201804098TA (en) | 2015-11-20 | 2018-06-28 | Forma Therapeutics Inc | Purinones as ubiquitin-specific protease 1 inhibitors |
WO2017136689A1 (en) * | 2016-02-05 | 2017-08-10 | Academia Sinica | Purine compounds possessing anticancer activity |
SG11201809702SA (en) | 2016-05-20 | 2018-12-28 | Xenon Pharmaceuticals Inc | Benzenesulfonamide compounds and their use as therapeutic agents |
AU2017345736B2 (en) | 2016-10-21 | 2022-04-07 | Takeda Pharmaceutical Company Limited | TYK2 inhibitors and uses thereof |
WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
JP7105774B2 (ja) | 2016-12-01 | 2022-07-25 | イグナイタ インコーポレイテッド | がん治療のための方法 |
CA3042004A1 (en) | 2016-12-09 | 2018-06-14 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
CN106729620A (zh) * | 2016-12-15 | 2017-05-31 | 杨明夏 | 人源性核糖体蛋白l22用作为抗癌抗肿瘤药物的新用途 |
JP7282045B2 (ja) | 2017-06-22 | 2023-05-26 | セルジーン コーポレイション | B型肝炎ウイルス感染を特徴とする肝細胞癌の治療 |
JP7196160B2 (ja) | 2017-09-12 | 2022-12-26 | スミトモ ファーマ オンコロジー, インコーポレイテッド | Mcl-1阻害剤アルボシジブを用いた、bcl-2阻害剤に対して非感受性である癌の治療レジメン |
MX2020004239A (es) * | 2017-11-01 | 2020-09-09 | Juno Therapeutics Inc | Proceso para producir una composicion de celulas t. |
KR20210019507A (ko) | 2018-06-13 | 2021-02-22 | 제논 파마슈티칼스 인크. | 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도 |
EP3844158A1 (en) | 2018-08-31 | 2021-07-07 | Xenon Pharmaceuticals Inc. | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors |
CN112638879A (zh) | 2018-08-31 | 2021-04-09 | 泽农医药公司 | 杂芳基取代的磺酰胺化合物及其作为治疗剂的用途 |
JP2022511029A (ja) | 2018-12-04 | 2022-01-28 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | がんの処置のための薬剤としての使用のためのcdk9インヒビターおよびその多形 |
US11793802B2 (en) | 2019-03-20 | 2023-10-24 | Sumitomo Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (AML) with venetoclax failure |
EP4003980A1 (en) * | 2019-07-31 | 2022-06-01 | Ribon Therapeutics Inc. | Heterobicyclic amides as inhibitors of cd38 |
WO2021130638A1 (en) * | 2019-12-24 | 2021-07-01 | Carna Biosciences, Inc. | Diacylglycerol kinase modulating compounds |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2852506A (en) * | 1955-10-31 | 1958-09-16 | American Cyanamid Co | Method of preparing aminodeoxyglycosidopurines |
US3325495A (en) * | 1965-01-26 | 1967-06-13 | American Home Prod | Purine carboxamides |
TW274550B (xx) | 1992-09-26 | 1996-04-21 | Hoechst Ag | |
JP2002100363A (ja) | 2000-09-25 | 2002-04-05 | Mitsubishi Chemicals Corp | リチウム二次電池用正極材料、リチウム二次電池用正極及びリチウム二次電池 |
WO2002076954A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
US7247621B2 (en) | 2002-04-30 | 2007-07-24 | Valeant Research & Development | Antiviral phosphonate compounds and methods therefor |
MXPA04010983A (es) | 2002-05-06 | 2005-02-14 | Genelabs Tech Inc | Derivados de nucleosidos para tratar infecciones por el virus de la hepatitis c. |
US7199119B2 (en) | 2002-10-31 | 2007-04-03 | Amgen Inc. | Antiinflammation agents |
SI2604620T1 (sl) | 2003-05-30 | 2016-10-28 | Gilead Pharmasset LLC c/o Gilead Sciences, Inc. | Modificirani fluorirani nukleozidni analogi |
US7855205B2 (en) | 2004-10-29 | 2010-12-21 | Janssen Pharmaceutica Nv | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
RU2405780C2 (ru) * | 2005-02-16 | 2010-12-10 | Астразенека Аб | Химические соединения |
US20080242685A1 (en) * | 2005-10-25 | 2008-10-02 | Smithkline Beecham Corporation | Chemical Compounds |
US20090281075A1 (en) * | 2006-02-17 | 2009-11-12 | Pharmacopeia, Inc. | Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors |
EP2063882A4 (en) * | 2006-09-05 | 2010-03-03 | Univ Emory | TYROSINKINASE INHIBITOR FOR PREVENTING OR TREATING INFECTIONS |
US20100144738A1 (en) * | 2006-09-05 | 2010-06-10 | William Bornmann | Inhibitors of c-met and uses thereof |
AR063142A1 (es) * | 2006-10-04 | 2008-12-30 | Pharmacopeia Inc | Derivados de 2-(bencimidazolil) purina y purinonas 6-sustituidas utiles como inmunosupresores,y composiciones farmaceuticas que los contienen. |
US7902187B2 (en) * | 2006-10-04 | 2011-03-08 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
AU2008345225A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
-
2007
- 2007-10-18 CN CN200780046579.3A patent/CN101679432B/zh active Active
- 2007-10-18 BR BRPI0717773-9A2A patent/BRPI0717773A2/pt not_active IP Right Cessation
- 2007-10-18 RU RU2009118617/04A patent/RU2474582C2/ru not_active IP Right Cessation
- 2007-10-18 WO PCT/US2007/022375 patent/WO2008051494A1/en active Application Filing
- 2007-10-18 AU AU2007309468A patent/AU2007309468B2/en active Active
- 2007-10-18 AT AT07861468T patent/ATE549336T1/de active
- 2007-10-18 CA CA2666624A patent/CA2666624C/en active Active
- 2007-10-18 US US11/975,657 patent/US7968556B2/en active Active
- 2007-10-18 EP EP07861468A patent/EP2078018B1/en active Active
- 2007-10-18 NZ NZ576279A patent/NZ576279A/en not_active IP Right Cessation
- 2007-10-18 ES ES07861468T patent/ES2383370T3/es active Active
- 2007-10-18 KR KR1020097010207A patent/KR101451290B1/ko not_active IP Right Cessation
- 2007-10-18 MX MX2009004019A patent/MX2009004019A/es active IP Right Grant
- 2007-10-18 JP JP2009533398A patent/JP5513119B2/ja active Active
- 2007-10-18 ZA ZA200902384A patent/ZA200902384B/xx unknown
-
2009
- 2009-04-07 IL IL198116A patent/IL198116A/en not_active IP Right Cessation
- 2009-11-25 HK HK09110989.3A patent/HK1131146A1/xx not_active IP Right Cessation
-
2011
- 2011-05-23 US US13/113,135 patent/US8383634B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
KR20090069195A (ko) | 2009-06-29 |
NZ576279A (en) | 2011-12-22 |
US20090042890A1 (en) | 2009-02-12 |
AU2007309468B2 (en) | 2012-05-17 |
IL198116A (en) | 2016-06-30 |
US7968556B2 (en) | 2011-06-28 |
AU2007309468A1 (en) | 2008-05-02 |
KR101451290B1 (ko) | 2014-10-15 |
ATE549336T1 (de) | 2012-03-15 |
JP5513119B2 (ja) | 2014-06-04 |
ES2383370T3 (es) | 2012-06-20 |
HK1131146A1 (en) | 2010-01-15 |
CN101679432A (zh) | 2010-03-24 |
WO2008051494A1 (en) | 2008-05-02 |
RU2474582C2 (ru) | 2013-02-10 |
JP2010506935A (ja) | 2010-03-04 |
EP2078018A1 (en) | 2009-07-15 |
BRPI0717773A2 (pt) | 2013-11-05 |
IL198116A0 (en) | 2009-12-24 |
RU2009118617A (ru) | 2010-11-27 |
MX2009004019A (es) | 2009-06-19 |
US8383634B2 (en) | 2013-02-26 |
EP2078018B1 (en) | 2012-03-14 |
CA2666624C (en) | 2015-12-29 |
CA2666624A1 (en) | 2008-05-02 |
US20110224217A1 (en) | 2011-09-15 |
CN101679432B (zh) | 2015-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1131146A1 (en) | Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors | |
MX2009004077A (es) | Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas. | |
WO2008036308A3 (en) | Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith | |
MX2009008439A (es) | Nuevos inhibidores de la replicacion del virus de hepatitis c. | |
EA200970486A1 (ru) | Соединения для ингибирования митоза | |
CO6531502A2 (es) | Aminotriazolopiridinas y su uso como inhibidores de cinasa | |
EA200970542A1 (ru) | ИНГИБИТОРЫ ДЕЙСТВИЯ Akt | |
GEP20146102B (en) | Compounds and compositions as protein kinase inhibitors | |
MY149512A (en) | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | |
WO2009155121A3 (en) | Inhibitors of pi3 kinase | |
MX2009011867A (es) | Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c. | |
TW200626610A (en) | Analogs of 17-hydroxywortmannin as PI3K inhibitors | |
EA201290183A1 (ru) | Бензодиазепиновый ингибитор бромодомена | |
SG179418A1 (en) | Inhibitors of the hedgehog pathway | |
TN2009000481A1 (en) | Novel peptide inhibitors of hepatitis c virus replication | |
MX2007013624A (es) | Inhibidores de proteina cinasa. | |
IL198901A0 (en) | Pyrimidine derivatives and multiple myeloma | |
MX2012003171A (es) | Novedosos inhibidores macrociclicos de la replicacion del virus de hepatitis c. | |
NO20085317L (no) | Imidazoazepinonforbindelser | |
WO2005105770A3 (en) | Arylphenylamino-, arylphenylamide-, and arylphenylether-sulfide derivatives | |
MX2008016358A (es) | Derivados de tiazolil-urea como inhibidores de cinasa de fosfatidil-inositol-3. | |
NZ592392A (en) | PHENANTHROINDOLIZIDINE COMPOUND AND NFkB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT | |
WO2005105766A3 (en) | Arylphenylamino-and arylphenylether-sulfide derivatives, useful for the treatment of inflammatory and immune diseases, and pharmaceutical compositions containing them | |
MX2009012079A (es) | Compuestos heterociclicos condensados como inhibidores de proteina cinasas. | |
TW200738703A (en) | 2-Carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof |